LOGIQ Totus
GE Medical Systems Ultrasound and Primary care Diagnostics, • Radiology • 12/07/2023
Device Purpose
The LOGIQ Totus is a general-purpose diagnostic ultrasound system utilizing established ultrasonic principles and advanced imaging modes for comprehensive visualization and analysis across a wide array of clinical applications. It features a mobile console design, integrates AI-driven software for enhanced workflow such as automated preset selection and color assistance, and supports specialized probes to facilitate detailed examinations in diverse medical settings.
Summary
The LOGIQ Totus is a full-featured, mobile diagnostic ultrasound system designed for use by qualified healthcare professionals. Its primary purpose is to provide digital acquisition, processing, display, and analysis of ultrasound images and fluid dynamics of the human body for a wide range of clinical applications. These applications include fetal/obstetrics, abdominal (renal, gynecology/pelvic), pediatric, small organs (breast, testes, thyroid), neonatal and adult cephalic, cardiac (adult and pediatric), peripheral vascular, musculoskeletal, urology (including prostate), transrectal, and transvaginal procedures. The system supports numerous operating modes such as B-mode, M-mode, Pulsed Wave (PW) Doppler, Continuous Wave (CW) Doppler, Color Doppler, Power Doppler, Harmonic Imaging, 3D/4D Imaging, Elastography, Shear Wave Elastography, Attenuation Imaging, and Contrast Enhanced Imaging, along with various combined modes. The LOGIQ Totus utilizes established scientific ultrasound technology, incorporating a user interface with a computer keyboard, a 14-inch LCD touchscreen, and a 23.8-inch LCD & HDU image display. It introduces advanced software capabilities, including AI-driven features like "Auto Preset Selection" and "Auto Abdominal Color Assistant," which are designed to suggest appropriate imaging views with an expected model success rate of 80% or higher, based on testing with over 40-50 patients and 280-330 images. Additional software enhancements include Vscan Air CL Support, VITA on demand, and Auto EF/AFI Enhancement. The system's probe compatibility is expanded with the addition of the 9S-D and 12S-D models, and it supports connectivity with the Vscan Air CL. The device has undergone evaluations for acoustic output, biocompatibility, and conforms to relevant electrical, electromagnetic, and mechanical safety standards, ensuring its materials are safe for intended use and acoustic power levels are within acceptable limits. It performs measurements, captures digital images, and facilitates review and reporting of studies, though it does not include Transesophageal and Intraoperative (Abdominal, Vascular) clinical applications.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. What specific image quality improvements or workflow efficiencies does the 'Auto Preset Selection' AI feature offer across the diverse range of supported clinical applications, such as fetal versus musculoskeletal imaging?; How does the performance of the 'Auto Abdominal Color Assistant,' with its 80% expected success rate, vary with patient BMI or specific abdominal pathologies, and what is the typical user intervention rate?; Given the addition of new probes (9S-D, 12S-D) migrated from the Vivid E80/E90/E95 R4, what new diagnostic capabilities or enhanced image quality do these specific probes bring to the LOGIQ Totus platform, particularly for cardiac applications?; The AI testing datasets included patients from the USA and Australia; were there any observed differences in AI algorithm performance between these populations, and how is the system validated for broader global demographic and anatomical variations?; While 'Transesophageal' and 'Intraoperative (Abdominal, Vascular)' applications are excluded, what is the rationale for these exclusions from the LOGIQ Totus's capabilities, and are there plans to incorporate them in future iterations?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM, SaaSBOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly